TY - JOUR
T1 - PD-L1 Expression in Cutaneous Angiosarcomas
T2 - A Systematic Review with Meta-Analysis
AU - Lobrano, Renato
AU - Paliogiannis, Panagiotis
AU - Zinellu, Angelo
AU - Palmieri, Giuseppe
AU - Persico, Ivana
AU - Mangoni, Arduino A.
AU - Cossu, Antonio
PY - 2023/5
Y1 - 2023/5
N2 - Cutaneous angiosarcoma (CAS) is the most common type of angiosarcoma that predominantly affects older Caucasians. The outcomes of immunotherapy in CAS are currently under investigation in relation to the expression of programmed death ligand 1 (PD-L1) and other biomarkers. We performed a systematic review and metanalysis of data from the current literature reporting on PD-L1 immunohistochemistry expression. A systematic search of publications in the electronic databases PubMed, Web of Science, and Scopus was conducted using the following terms: “PD-L1” and “angiosarcomas”. A total of ten studies reporting on 279 cases were identified and included in the meta-analysis. The pooled prevalence of PD-L1 expression in CAS was 54% (95% CI 36–71%), with high heterogeneity (I2 = 84.81%, p < 0.001). In sub-group analysis, the proportion of PD-L1 expression in CAS was significantly (p = 0.049) lower in Asian studies (ES = 35%, 95% CI 28–42%, I2 = 0.0%, p = 0.46) than in European studies (ES = 71%, 95% CI 51–89%, I2 = 48.91%, p = 0.12).
AB - Cutaneous angiosarcoma (CAS) is the most common type of angiosarcoma that predominantly affects older Caucasians. The outcomes of immunotherapy in CAS are currently under investigation in relation to the expression of programmed death ligand 1 (PD-L1) and other biomarkers. We performed a systematic review and metanalysis of data from the current literature reporting on PD-L1 immunohistochemistry expression. A systematic search of publications in the electronic databases PubMed, Web of Science, and Scopus was conducted using the following terms: “PD-L1” and “angiosarcomas”. A total of ten studies reporting on 279 cases were identified and included in the meta-analysis. The pooled prevalence of PD-L1 expression in CAS was 54% (95% CI 36–71%), with high heterogeneity (I2 = 84.81%, p < 0.001). In sub-group analysis, the proportion of PD-L1 expression in CAS was significantly (p = 0.049) lower in Asian studies (ES = 35%, 95% CI 28–42%, I2 = 0.0%, p = 0.46) than in European studies (ES = 71%, 95% CI 51–89%, I2 = 48.91%, p = 0.12).
KW - cancer
KW - cutaneous angiosarcomas
KW - immunohistochemistry
KW - immunotherapy
KW - PD-L1
KW - skin
UR - http://www.scopus.com/inward/record.url?scp=85160253367&partnerID=8YFLogxK
U2 - 10.3390/curroncol30050388
DO - 10.3390/curroncol30050388
M3 - Review article
C2 - 37232846
AN - SCOPUS:85160253367
SN - 1718-7729
VL - 30
SP - 5135
EP - 5144
JO - Current Oncology
JF - Current Oncology
IS - 5
ER -